Zhongguancun: Four new varieties of its subsidiary companies have entered the "National Essential Drug List", and one variety has been removed.

The announcement from Zhongguancun stated that the "National Essential Medicine List" will be implemented starting from September 1st. 14 products of the company's subsidiaries have been included in the list, with 4 new products added and 1 product removed. The sales revenue of the company's strategic product Hydrocortisone Sodium Succinate Injection is expected to increase by 121.95% in 2025, and its inclusion in the "Essential Medicine List" will strengthen the company's advantages. The addition of new products will help expand coverage and is expected to have a positive long-term impact on development, but drug sales are influenced by various factors, leading to uncertainty.